,name,type,study_title,group_id,study_type,description,has_placebo,has_drug
0,Gabapentin,primary,"A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children",OG000,Crossover Assignment,"Neurotin

Gabapentin: The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.",False,True
1,Placebo,primary,"A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children",OG001,Crossover Assignment,"Glycerin based clear solution that is flavored similar to the commercial product

placebo",True,False
2,Gabapentin,primary,"Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy: A Prospective Double-blinded, Placebo Controlled Randomized Study",OG000,Parallel Assignment,Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.,False,True
3,Placebo,primary,"Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy: A Prospective Double-blinded, Placebo Controlled Randomized Study",OG001,Parallel Assignment,Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.,True,False
4,Gabapentin,primary,Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction,OG000,Parallel Assignment,"Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.

Gabapentin",False,True
5,Simple Syrup,primary,Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction,OG001,Parallel Assignment,"Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.

Simple Syrup",False,False
6,Gralise (Gabapentin ER),primary,"Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.",OG000,Single Group Assignment,"An Open label trial with Gralise. All subjects on gabapentinoids will require wash before starting trial.

All Subjects will follow the instructions on the Gralise starter pack with eventual goal of 1800 mg/day.

Subjects will be have follow up visits every 4 weeks, and at the end of 12 weeks, subjects will begin to wash off of Gralise. Visit 5 will be end of the study/ treatment visit.

Subject will rate pain ratings as primary outcome measure, and fibromyalgia impact questionnaires, medical study's outcome sleep scores, and patients global impression of change (PGIC) as secondary outcome measures. Subjects are assessed at each follow up visits for adverse events, and concomitant medication changes if any.",False,True
7,Placebo,primary,Gabapentin for Smoking Abstinence,OG000,Parallel Assignment,Placebo pill was identical in appearance to the active medication. Initial dosage consisted of 1 pill by mouth in the morning and night. The dose was increased over the first 2 weeks to the target frequency of three times a day. This dose was continued for the next 9 weeks and tapered in the last week. The medication was stopped at the end of 12 weeks.,True,False
8,Gabapentin - 1800 mg /Day,primary,Gabapentin for Smoking Abstinence,OG001,Parallel Assignment,Gabapentin was initiated at a dose of 300 mg by mouth in the morning and night. The dose was increased over the first 2 weeks to the target doses of 600 mg three times a day. This dose was continued for the next 9 weeks and tapered in the last week. The medication was stopped at the end of 12 weeks.,False,True
9,Gabapentin - 2700 mg/Day,primary,Gabapentin for Smoking Abstinence,OG002,Parallel Assignment,Gabapentin was initiated at a dose of 300 mg by mouth in the morning and night. The dose was increased over the first 2 weeks to the target doses of 900 mg three times a day. This dose was continued for the next 9 weeks and tapered in the last week. The medication was stopped at the end of 12 weeks.,False,True
10,Active Medication,primary,A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients,OG000,Parallel Assignment,"gabapentin treatment 1200 mg three times daily

Gabapentin: For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.",False,False
11,Placebo,primary,A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients,OG001,Parallel Assignment,"Placebo condition received pills identical in appearance to experimental arm.

Gabapentin: For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.",True,False
12,Open-label Gabapentin,primary,Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.,OG000,Single Group Assignment,"Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.

Gabapentin: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.",False,True
13,Open-label Gabapentin,primary,Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.,OG000,Single Group Assignment,"Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.

Gabapentin: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.",False,True
14,Open-label Gabapentin,primary,Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.,OG000,Single Group Assignment,"Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.

Gabapentin: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.",False,True
15,Open-label Gabapentin,primary,Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.,OG000,Single Group Assignment,"Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.

Gabapentin: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.",False,True
16,Open-label Gabapentin,primary,Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.,OG000,Single Group Assignment,"Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.

Gabapentin: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.",False,True
17,Open-label Gabapentin,primary,Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.,OG000,Single Group Assignment,"Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.

Gabapentin: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.",False,True
18,Gabapentin,primary,Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain in Surgical Patients,OG000,Parallel Assignment,"Double blind, placebo controlled

Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days",False,True
19,Placebo,primary,Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain in Surgical Patients,OG001,Parallel Assignment,"Double blind

Gabapentin: This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days",True,False
20,Gabapentin,primary,Gabapentin for Abstinence Initiation in Alcohol Dependence,OG000,Parallel Assignment,"Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.

Gabapentin: During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.",False,True
21,Placebo,primary,Gabapentin for Abstinence Initiation in Alcohol Dependence,OG001,Parallel Assignment,"Placebo capsules will be administered TID.

Placebo: Placebo, TID",True,False
22,Gabapentin 1200mg/Day,primary,Gabapentin Treatment of Cannabis Dependence,OG000,Parallel Assignment,1200mg/day of gabapentin given in conjunction with standardized manual-guided behavioral counseling.,False,True
23,Placebo,primary,Gabapentin Treatment of Cannabis Dependence,OG001,Parallel Assignment,Matched placebo given in conjunction with standardized manual-guided behavioral counseling.,True,False
24,Hypnotherapy,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG000,Parallel Assignment,Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of self-hypnosis techniques to use at home.,False,False
25,Gabapentin,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG001,Parallel Assignment,Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily).,False,True
26,Hypnotherapy,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG000,Parallel Assignment,Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of self-hypnosis techniques to use at home.,False,False
27,Gabapentin,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG001,Parallel Assignment,Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily).,False,True
28,Hypnotherapy,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG000,Parallel Assignment,Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of self-hypnosis techniques to use at home.,False,False
29,Gabapentin,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG001,Parallel Assignment,Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily).,False,True
30,Hypnotherapy,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG000,Parallel Assignment,Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of self-hypnosis techniques to use at home.,False,False
31,Gabapentin,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG001,Parallel Assignment,Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily).,False,True
32,Hypnotherapy,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG000,Parallel Assignment,Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of self-hypnosis techniques to use at home.,False,False
33,Gabapentin,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG001,Parallel Assignment,Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily).,False,True
34,Hypnotherapy,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG000,Parallel Assignment,Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. Patients will also be instructed on the use of self-hypnosis techniques to use at home.,False,False
35,Gabapentin,primary,Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.,OG001,Parallel Assignment,Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily).,False,True
36,Arm A: Gabapentin,primary,"Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer",OG000,Parallel Assignment,"Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.

Gabapentin: Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.",False,True
37,Arm B: Venlafaxine,primary,"Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer",OG001,Parallel Assignment,"Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.

Venlafaxine: Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.",False,False
38,Gabapentin Arm,primary,Gabapentin for Perioperative Pain Relief in Surgical Abortion: a Double-blind Randomized Controlled Trial,OG000,Parallel Assignment,"Gabapentin 600 mg given 1-2 hours prior to surgical abortion

Gabapentin: Preoperative treatment with Gabapentin",False,True
39,Placebo Arm,primary,Gabapentin for Perioperative Pain Relief in Surgical Abortion: a Double-blind Randomized Controlled Trial,OG001,Parallel Assignment,"Placebo (vit C) given 1-2 hours prior to surgical abortion

Placebos: Preoperative treatment with Placebo",True,False
40,Gabapentin,primary,"An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects",OG000,Single Group Assignment,"The dosage of oral solution for subjects aged 3 to 12 years was calculated based on their body weight. The dose was titrated for the first 3 days of the treatment period. Subjects aged 3 to 4 years received gabapentin 10 mg/kg/day on Day 1, 20 mg/kg/day on Day 2 and 40 mg/kg/day from Day 3. Subjects aged 5 to 12 years received gabapentin 10 mg/kg/day on Day 1, 20 mg/kg/day on Day 2 and 25 to 35 mg/kg/day from Day 3. Subjects aged 13 to 15 years received gabapentin 600 mg/day on Day 1, 1200 mg/day on Day 2 and 1200 or 1800 mg/day from Day 3. After Day 3, the dose was adjusted if necessary within the range of maintenance doses. The maximum daily dose was 600 mg for Day 1, 1200 mg for Day 2, and 1800 mg for Day 3 and thereafter.",False,True
41,Sugar Pill,primary,"Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder",OG000,Parallel Assignment,"Matching placebo, sugar pill

Placebo: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day",False,False
42,Gabapentin Enacarbil,primary,"Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder",OG001,Parallel Assignment,"600 mg Gabapentin Enacarbil (Horizant)

gabapentin enacarbil: Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day",False,True
43,Gabapentin,primary,Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage,OG000,Parallel Assignment,"Gabapentin capsules 100 mg TID, 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.

Gabapentin: Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.

Both groups will receive other standard of care pain medications.",False,True
44,Control,primary,Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage,OG001,Parallel Assignment,"Placebo capsules 100 mg TID, 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.

Placebo: Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.

Both groups will receive other standard of care pain medications.",False,False
45,Gabapentin,primary,Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage,OG000,Parallel Assignment,"Gabapentin capsules 100 mg TID, 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.

Gabapentin: Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.

Both groups will receive other standard of care pain medications.",False,True
46,Control,primary,Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage,OG001,Parallel Assignment,"Placebo capsules 100 mg TID, 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.

Placebo: Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.

Both groups will receive other standard of care pain medications.",False,False
47,"Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules",primary,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",OG000,Parallel Assignment,"amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily",True,False
48,"Gabapentin Capsules, Placebo Cream",primary,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",OG001,Parallel Assignment,oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily,True,True
49,Placebo Cream and Capsules,primary,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",OG002,Parallel Assignment,"placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily",True,False
50,"Amitriptyline 4% Ketamine 2% Cream, Placebo Capsules",primary,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",OG000,Parallel Assignment,"amitriptyline 4% ketamine 2% cream 4grams applied twice daily to affected area, placebo capsules taken orally 3 times daily",True,False
51,"Gabapentin Capsules, Placebo Cream",primary,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",OG001,Parallel Assignment,oral gabapentin capsules 600mg three times daily and placebo cream applied 4 grams twice daily,True,True
52,Placebo Cream and Capsules,primary,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)",OG002,Parallel Assignment,"placebo NP-1 cream 4gms applied twice daily and placebo gabapentin capsules, taken orally 3 times daily",True,False
53,Gabapentin Group,primary,Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial,OG000,Parallel Assignment,Participants receiving local anesthesia per clinic protocol plus two 300mg capsules of gabapentin 1-2 hours prior to the procedure.,False,True
54,Placebo Group,primary,Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial,OG001,Parallel Assignment,Participants receiving local anesthesia per clinic protocol plus two 300mg capsules of a placebo to match gabapentin 1-2 hours prior to the procedure.,True,False
55,Gabapentin Preoperatively,primary,"Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study",OG000,Parallel Assignment,Preoperative gabapentin 600 mg p.o. within 2 hours prior to surgery.,False,True
56,Active Placebo,primary,"Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study",OG001,Parallel Assignment,Diphenhydramine 12.5 mg p.o. 2 hours preoperatively.,True,False
57,Gabapentin Preoperatively,primary,"Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study",OG000,Parallel Assignment,Preoperative gabapentin 600 mg p.o. within 2 hours prior to surgery.,False,True
58,Active Placebo,primary,"Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study",OG001,Parallel Assignment,Diphenhydramine 12.5 mg p.o. 2 hours preoperatively.,True,False
59,Gabapentin Preoperatively,primary,"Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study",OG000,Parallel Assignment,Preoperative gabapentin 600 mg p.o. within 2 hours prior to surgery.,False,True
60,Active Placebo,primary,"Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study",OG001,Parallel Assignment,Diphenhydramine 12.5 mg p.o. 2 hours preoperatively.,True,False
61,Group 1: Placebo,primary,Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration: a Randomized Controlled Trial,OG000,Parallel Assignment,"Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.

Placebo: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure",True,False
62,Group 2: Gabapentin,primary,Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration: a Randomized Controlled Trial,OG001,Parallel Assignment,"Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.

Gabapentin: 600mg Gabapentin administered orally 1-2 hours prior to procedure",False,True
63,Gabapentin,primary,"Vulvar Pain: Treatment Trial Using Gabapentin-placebo in a Cross-over Design, Pilot Study.",OG000,Crossover Assignment,NA,False,True
64,Placebo,primary,"Vulvar Pain: Treatment Trial Using Gabapentin-placebo in a Cross-over Design, Pilot Study.",OG001,Crossover Assignment,NA,True,False
65,Placebo,primary,A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response,OG000,Crossover Assignment,2 capsules am and 3 capsules pm,True,False
66,Gabapentin,primary,A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response,OG001,Crossover Assignment,2 capsules (1200 mg) am and 3 capsules (1800 mg) pm,False,True
67,Gabapentin,primary,Randomized Controlled Trial of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse,OG000,Parallel Assignment,"Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg BID for an additional 11 days.

Gabapentin: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.",False,True
68,Placebo Oral Capsule,primary,Randomized Controlled Trial of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse,OG001,Parallel Assignment,"Participants will take placebo for the 2 weeks after surgery.

Placebo oral capsule: Patients randomized to this arm will receive 2 weeks of placebo post-operatively..",True,False
69,Gabapentin,primary,A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment,OG000,Single Group Assignment,"The dosage regimens were adjusted depending on the creatinine clearance. Duration of observation was 15 days from screening if the subject had already been treated with gabapentin and 28 days from screening if the subject was treated with gabapentin for the first time.

The subject enrolled was on hemodialysis, receiving a maintenance dose of 300 mg twice daily for 15 days.",False,True
70,Gabapentin,primary,A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment,OG000,Single Group Assignment,"The dosage regimens were adjusted depending on the creatinine clearance. Duration of observation was 15 days from screening if the subject had already been treated with gabapentin and 28 days from screening if the subject was treated with gabapentin for the first time.

The subject enrolled was on hemodialysis, receiving a maintenance dose of 300 mg twice daily for 15 days.",False,True
71,Gabapentin,primary,A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment,OG000,Single Group Assignment,"The dosage regimens were adjusted depending on the creatinine clearance. Duration of observation was 15 days from screening if the subject had already been treated with gabapentin and 28 days from screening if the subject was treated with gabapentin for the first time.

The subject enrolled was on hemodialysis, receiving a maintenance dose of 300 mg twice daily for 15 days.",False,True
72,Gabapentin/Morphine,primary,Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients,OG000,Parallel Assignment,Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.,False,True
73,Placebo/Morphine,primary,Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients,OG001,Parallel Assignment,Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.,True,False
74,Gabapentin/Morphine,primary,Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients,OG000,Parallel Assignment,Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.,False,True
75,Placebo/Morphine,primary,Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients,OG001,Parallel Assignment,Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.,True,False
76,Gabapentin/Morphine,primary,Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients,OG000,Parallel Assignment,Gabapentin - group received gabapentin 3 times daily 5 mg/kg/dose. *Both groups received Morphine as needed.,False,True
77,Placebo/Morphine,primary,Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients,OG001,Parallel Assignment,Placebo Comparator - group received placebo 3 times daily. *Both groups received Morphine as needed.,True,False
78,Gabapentin,primary,"Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.",OG000,Parallel Assignment,"Neurontin

Gabapentin: Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days",False,True
79,Pregabalin,primary,"Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.",OG001,Parallel Assignment,"Lyrica

pregabalin: 50 mg PO TID",False,False
80,CRPS I Pain Subjects,primary,Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise),OG000,Single Group Assignment,"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.

Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day",False,False
81,Standard Sedation,primary,Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial,OG000,Parallel Assignment,"Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.",False,False
82,Gapabentin,primary,Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial,OG001,Parallel Assignment,"Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.",False,False
83,Gabapentin,primary,Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial,OG000,Parallel Assignment,"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)

Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight

Gabapentin 600mg: Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)

acetaminophen/codeine and ibuprofen: Over the counter analgesic medications",False,True
84,Placebo Oral Capsule,primary,Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial,OG001,Parallel Assignment,"Matched placebo

Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight

Placebo oral capsule: Packaged identical to gabapentin dosing

acetaminophen/codeine and ibuprofen: Over the counter analgesic medications",True,False
85,Gabapentin,primary,Gabapentin for Bipolar & Cannabis Use Disorders,OG000,Crossover Assignment,"Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).

Gabapentin: 5 day trial of gabapentin with titration to 1,200mg",False,True
86,Placebo Oral Capsule,primary,Gabapentin for Bipolar & Cannabis Use Disorders,OG001,Crossover Assignment,"Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).

Placebo Oral Capsule: 5 day trial of matched placebo",True,False
87,Chlordiazepoxide,primary,Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment,OG000,Parallel Assignment,"25mg four times daily x 3 days, 25mg three times daily x 1 day, 25mg twice daily x 1 day, 25mg at bedtime x 1 day then discontinue",False,False
88,Gabapentin,primary,Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment,OG001,Parallel Assignment,"300mg four times daily x 3 days, 300mg three times daily x 1 day, 300mg twice daily x 1 day, 300mg at bedtime x 1 day then discontinue",False,True
89,Chlordiazepoxide,primary,Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment,OG000,Parallel Assignment,"25mg four times daily x 3 days, 25mg three times daily x 1 day, 25mg twice daily x 1 day, 25mg at bedtime x 1 day then discontinue",False,False
90,Gabapentin,primary,Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment,OG001,Parallel Assignment,"300mg four times daily x 3 days, 300mg three times daily x 1 day, 300mg twice daily x 1 day, 300mg at bedtime x 1 day then discontinue",False,True
91,Gabapentin 900mg Daily,primary,Gabapentin Treatment of Alcohol Dependence,OG000,Parallel Assignment,"900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.

Gabapentin 900mg: 900 mg gabapentin daily for 12 weeks

behavioral counseling: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.",False,True
92,Gabapentin 1800mg Daily,primary,Gabapentin Treatment of Alcohol Dependence,OG001,Parallel Assignment,"1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks

behavioral counseling: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.

gabapentin 1800mg: 1800 mg gabapentin daily for 12 weeks",False,True
93,Placebo Daily,primary,Gabapentin Treatment of Alcohol Dependence,OG002,Parallel Assignment,"placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.

behavioral counseling: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.

placebo: lactose capsule compounded to mimic gabapentin capsules",True,False
94,Gabapentin,primary,"A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)",OG000,Single Group Assignment,Pediatric participants received gabapentin three times daily for 52 weeks. Participants aged 3 to 12 years received oral solution (250 mg/5 mL) at the dose calculated based on their body weight; 40 mg/kg/day for 3 to 4 years old and 25 to 35 mg/kg/day for 5 to 12 years old but not exceeding 1800 mg per day. Participants aged 13 to 15 years received gabapentin tablet at the dose of 1200 or 1800 mg/day. The dose was adjusted within the range of maintenance doses. Gabapentin could be increased if necessary with the maximum dose of 50 mg/kg/day for participants aged 3 to 12 years; All participants could receive gabapentin tablet not exceeding 2400 mg per day.,False,True
95,Gabapentin,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG000,Parallel Assignment,Gabapentin 300mg taken by mouth thrice daily for 7 days,False,True
96,Placebo,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG001,Parallel Assignment,placebo (sugar pill) taken by mouth thrice daily for 7 days,True,False
97,Gabapentin,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG000,Parallel Assignment,Gabapentin 300mg taken by mouth thrice daily for 7 days,False,True
98,Placebo,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG001,Parallel Assignment,placebo (sugar pill) taken by mouth thrice daily for 7 days,True,False
99,Gabapentin,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG000,Parallel Assignment,Gabapentin 300mg taken by mouth thrice daily for 7 days,False,True
100,Placebo,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG001,Parallel Assignment,placebo (sugar pill) taken by mouth thrice daily for 7 days,True,False
101,Gabapentin,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG000,Parallel Assignment,Gabapentin 300mg taken by mouth thrice daily for 7 days,False,True
102,Placebo,primary,"Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial",OG001,Parallel Assignment,placebo (sugar pill) taken by mouth thrice daily for 7 days,True,False
103,Placebo,primary,"Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome.",OG000,Parallel Assignment,Placebo was administered orally once daily after the evening meal.,True,False
104,Gabapentin Enacarbil,primary,"Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome.",OG001,Parallel Assignment,Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week (upward titration period) followed by gabapentin enacarbil 600 mg for 11 weeks.,False,True
105,Control Group,primary,"Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study",OG000,Parallel Assignment,"Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)

Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy

Placebo:

Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily",False,False
106,Gabapentin,primary,"Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study",OG001,Parallel Assignment,"Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)

Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy

Gabapentin 300mg:

Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily",False,True
107,Control Group,primary,"Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study",OG000,Parallel Assignment,"Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)

Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy

Placebo:

Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily",False,False
108,Gabapentin,primary,"Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study",OG001,Parallel Assignment,"Dexamethasone 10mg + Ondansetron 8mg + Ranitidine 50mg , IV, before chemotherapy infusion (D1)

Dexamethasone 8mg orally 24h (day 2) and 48h (day 3) after chemotherapy

Gabapentin 300mg:

Five and four days before chemotherapy (day -5 and day -4): 1x daily
Three and two days before chemotherapy (day -3 and day -2): 2x daily
One day before to five days after chemotherapy ( day -1 to day 5): 3x daily",False,True
109,Gabapentin,primary,Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus,OG000,Crossover Assignment,"Increasing dose to 300 mg four times per day (total of 1200 mg/day)

gabapentin: increasing to 1200 mg/day",False,True
110,Memantine,primary,Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus,OG001,Crossover Assignment,"Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).

memantine: increasing to 40 mg/day",False,False
111,Gabapentin,primary,Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus,OG000,Crossover Assignment,"Increasing dose to 300 mg four times per day (total of 1200 mg/day)

gabapentin: increasing to 1200 mg/day",False,True
112,Memantine,primary,Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus,OG001,Crossover Assignment,"Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).

memantine: increasing to 40 mg/day",False,False
113,Arm I (Gabapentin),primary,Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy,OG000,Parallel Assignment,"Patients receive gabapentin PO TID for 48 hours after surgery.

Gabapentin: Given PO

Questionnaire Administration: Ancillary studies",False,True
114,Arm II (Placebo),primary,Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy,OG001,Parallel Assignment,"Patients receive placebo PO TID for 48 hours after surgery.

Placebo: Given PO

Questionnaire Administration: Ancillary studies",True,False
115,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Parallel Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
116,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Parallel Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
117,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Parallel Assignment,Placebo 1200 mg or 1800 mg,False,False
118,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Parallel Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
119,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Parallel Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
120,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Parallel Assignment,Placebo 1200 mg or 1800 mg,False,False
121,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Parallel Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
122,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Parallel Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
123,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Parallel Assignment,Placebo 1200 mg or 1800 mg,False,False
124,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Parallel Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
125,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Parallel Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
126,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Parallel Assignment,Placebo 1200 mg or 1800 mg,False,False
127,Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
128,Matched Controls for Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
129,Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
130,Matched Controls for Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
131,Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
132,Matched Controls for Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
133,Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
134,Matched Controls for Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
135,Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
136,Matched Controls for Incident All-cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
137,Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident stomach cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
138,Matched Controls for Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident stomach cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
139,Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident stomach cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
140,Matched Controls for Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident stomach cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
141,Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident stomach cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
142,Matched Controls for Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident stomach cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
143,Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident stomach cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
144,Matched Controls for Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident stomach cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
145,Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident stomach cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
146,Matched Controls for Incident Stomach Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident stomach cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
147,Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident anal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
148,Matched Controls for Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident anal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
149,Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident anal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
150,Matched Controls for Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident anal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
151,Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident anal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
152,Matched Controls for Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident anal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
153,Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident anal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
154,Matched Controls for Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident anal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
155,Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident anal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
156,Matched Controls for Incident Anal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident anal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
157,Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident lung cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
158,Matched Controls for Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident lung cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
159,Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident lung cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
160,Matched Controls for Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident lung cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
161,Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident lung cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
162,Matched Controls for Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident lung cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
163,Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident lung cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
164,Matched Controls for Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident lung cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
165,Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident lung cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
166,Matched Controls for Incident Lung Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident lung cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice",False,False
167,Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
168,Matched Controls for Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
169,Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
170,Matched Controls for Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
171,Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
172,Matched Controls for Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
173,Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
174,Matched Controls for Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
175,Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
176,Matched Controls for Incident Bone/Joint Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
177,Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident breast cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
178,Matched Controls for Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident breast cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
179,Cases,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Cases,False,False
180,Controls,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,Controls,False,False
181,Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident breast cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
182,Matched Controls for Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident breast cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
183,Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident breast cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
184,Matched Controls for Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident breast cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
185,Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident breast cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
186,Matched Controls for Incident Breast Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident breast cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
187,Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident penile cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
188,Matched Controls for Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident penile cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
189,Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident penile cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
190,Matched Controls for Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident penile cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
191,Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident penile cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
192,Matched Controls for Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident penile cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
193,Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident penile cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
194,Matched Controls for Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident penile cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
195,Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident penile cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
196,Matched Controls for Incident Penile Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident penile cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
197,Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bladder cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
198,Matched Controls for Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bladder cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
199,Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bladder cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
200,Matched Controls for Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bladder cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
201,Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bladder cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
202,Matched Controls for Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bladder cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
203,Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bladder cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
204,Matched Controls for Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bladder cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
205,Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident bladder cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
206,Matched Controls for Incident Bladder Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident bladder cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
207,Incident Other Nervous System Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident other nervous system cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
208,Matched Controls for Incident ONS Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident other nervous system cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
209,Incident Other Nervous System Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident other nervous system cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
210,Matched Controls for Incident ONS Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident other nervous system cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
211,Incident Other Nervous System Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident other nervous system cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
212,Matched Controls for Incident ONS Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident other nervous system cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
213,Incident Other Nervous System Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident other nervous system cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
214,Matched Controls for Incident ONS Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident other nervous system cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
215,Incident Other Nervous System Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident other nervous system cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
216,Matched Controls for Incident ONS Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident other nervous system cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
217,Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident pancreatic cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
218,Matched Controls for Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident pancreatic cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
219,Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident pancreatic cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
220,Matched Controls for Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident pancreatic cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
221,Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident pancreatic cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
222,Matched Controls for Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident pancreatic cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
223,Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident pancreatic cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
224,Matched Controls for Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident pancreatic cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
225,Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident pancreatic cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
226,Matched Controls for Incident Pancreatic Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident pancreatic cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
227,Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident renal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
228,Matched Controls for Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident renal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
229,Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident renal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
230,Matched Controls for Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident renal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
231,Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident renal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
232,Matched Controls for Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident renal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
233,Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident renal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
234,Matched Controls for Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident renal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
235,Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG000,NA,Patients with incident renal cancer defined from READ/OXMIS codes in the years 1995-2008,False,False
236,Matched Controls for Incident Renal Cancer Patients,primary,Risk of Cancer in Patients Exposed to Gabapentin in the GPRD,OG001,NA,"Cancer-free control patients risk set matched with incident renal cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site",False,False
237,Tramadol Hydrochloride/ Acetaminophen,primary,"Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study",OG000,Parallel Assignment,"Participants received 1 tablet containing tramadol hydrochloride (HCl) 37.5 milligram (mg) and acetaminophen 325 mg, once daily, at bed time on Day 1 to 3, 1 tablet twice daily on Day 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there was no pain relief, the dosage were increased up to 8 tablets per day for Day 15 to 28. The increased dose was maintained for Day 29 to 42.",False,False
238,Gabapentin,primary,"Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study",OG001,Parallel Assignment,"Participants received gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg was administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there was no pain relief, the dosage were increased up to 3600 mg per day for Day 15 to 28. The increased dose was maintained for Day 29 to 42.",False,True
239,Epidural Steroid Injection,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG000,Parallel Assignment,This group received an epidural steroid injection and placebo medication.,False,False
240,Gabapentin,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG001,Parallel Assignment,This group received gabapentin medication and a placebo injection.,False,True
241,Gabapentin Group,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG000,Parallel Assignment,This group received gabapentin and a placebo intramuscular injection.,False,True
242,Epidural Steroid,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG001,Parallel Assignment,This group received an epidural steroid injection and placebo gabapentin.,False,False
243,Epidural Steroid Injection,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG000,Parallel Assignment,This group received an epidural steroid injection and placebo medication.,False,False
244,Gabapentin,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG001,Parallel Assignment,This group received gabapentin medication and a placebo injection.,False,True
245,Epidural Steroid Injection,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG000,Parallel Assignment,This group received an epidural steroid injection and placebo medication.,False,False
246,Gabapentin,primary,"Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy",OG001,Parallel Assignment,This group received gabapentin medication and a placebo injection.,False,True
247,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
248,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
249,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
250,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
251,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
252,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
253,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
254,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
255,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
256,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
257,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
258,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
259,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
260,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
261,Cases,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG000,NA,Cases,False,False
262,Controls,primary,Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database,OG001,NA,Controls,False,False
263,1 Preoperative Gabapentin Liquid,primary,The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients,OG000,Crossover Assignment,"Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)

Gabapentin: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)",False,True
264,2 Preoperative and Postoperative Gabapentin Liquid,primary,The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients,OG001,Crossover Assignment,"Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)

Gabapentin: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)",False,True
265,3 Preoperative and Postoperative Placebo Liquid,primary,The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients,OG002,Crossover Assignment,"Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)

Placebo: Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)",True,False
266,1 Preoperative Gabapentin Liquid,primary,The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients,OG000,Crossover Assignment,"Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)

Gabapentin: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)",False,True
267,2 Preoperative and Postoperative Gabapentin Liquid,primary,The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients,OG001,Crossover Assignment,"Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)

Gabapentin: Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)",False,True
268,3 Preoperative and Postoperative Placebo Liquid,primary,The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients,OG002,Crossover Assignment,"Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)

Placebo: Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)",True,False
269,"Gabapentin 200, 300, 400 mg Tablets",primary,Drug Use Investigation Of Gabapen,OG000,NA,"The usual dosage of gabapentin in adults and children aged 13 or older was as follows: oral gabapentin 600 mg, 3 div., was administered on day 1 and an effective dose of 1200 mg, 3 div., was administered on day 2. From day 3 on, oral gabapentin 1200 mg to 1800 mg, 3 div., was administered as the maintenance dose. Subsequently, the maintenance dose was suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).",False,True
270,"Gabapentin 200, 300, 400 mg Tablets",primary,Drug Use Investigation Of Gabapen,OG000,NA,"The usual dosage of gabapentin in adults and children aged 13 or older was as follows: oral gabapentin 600 mg, 3 div., was administered on day 1 and an effective dose of 1200 mg, 3 div., was administered on day 2. From day 3 on, oral gabapentin 1200 mg to 1800 mg, 3 div., was administered as the maintenance dose. Subsequently, the maintenance dose was suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).",False,True
271,"Gabapentin 200, 300, 400 mg Tablets",primary,Drug Use Investigation Of Gabapen,OG000,NA,"The usual dosage of gabapentin in adults and children aged 13 or older was as follows: oral gabapentin 600 mg, 3 div., was administered on day 1 and an effective dose of 1200 mg, 3 div., was administered on day 2. From day 3 on, oral gabapentin 1200 mg to 1800 mg, 3 div., was administered as the maintenance dose. Subsequently, the maintenance dose was suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).",False,True
272,Gabapentin,primary,Gabapentin for Cannabis Withdrawal and Use,OG000,Parallel Assignment,1200 mg/daily of Gabapentin,False,True
273,Placebo,primary,Gabapentin for Cannabis Withdrawal and Use,OG001,Parallel Assignment,Matched Placebo,True,False
274,Gabapentin,primary,Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management,OG000,Parallel Assignment,"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:

Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules

Gabapentin

Acetaminophen

Celecoxib",False,True
275,Control,primary,Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management,OG001,Parallel Assignment,"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:

Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules

Acetaminophen

Celecoxib",False,False
276,Gabapentin,primary,Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management,OG000,Parallel Assignment,"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:

Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules

Gabapentin

Acetaminophen

Celecoxib",False,True
277,Control,primary,Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management,OG001,Parallel Assignment,"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:

Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules

Acetaminophen

Celecoxib",False,False
278,Gabapentin,primary,Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects,OG000,Parallel Assignment,"Gabapentin up to 1200 mg per day in 3 divided doses

Gabapentin: gaba potentiating medication",False,True
279,Placebo,primary,Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects,OG001,Parallel Assignment,"matching placebo

Placebo: a pill that looks exactly like the active medication but does not contain medication",True,False
280,Placebo Then Gralise,primary,Efficacy of Gralise® for Chronic Pelvic Pain,OG000,Crossover Assignment,"Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.",True,False
281,Gralise Then Placebo,primary,Efficacy of Gralise® for Chronic Pelvic Pain,OG001,Crossover Assignment,"Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.",True,False
282,Gabapentin,primary,Pain Management of Vaso-Occlusive Crisis in Children and Young Adults With Sickle Cell Disease,OG000,Parallel Assignment,"Participants were randomized to receive one dose of gabapentin.

Gabapentin: Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm received a single dose of gabapentin as soon after enrollment as feasible, given orally, approximately 15 mg/kg with a maximum dose of 900 mg.",False,True
283,Placebo,primary,Pain Management of Vaso-Occlusive Crisis in Children and Young Adults With Sickle Cell Disease,OG001,Parallel Assignment,"Participants were randomized to receive one dose of placebo.

Placebo: Placebo was prepared by the SJCRH pharmacy, similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm received a single dose of placebo as soon after enrollment as feasible, given orally, in a volume that matched the active medication arm.",True,False
284,Gabapentin,primary,Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial,OG000,Parallel Assignment,Gabapentin liquid by mouth or per Tube 300mg twice a day,False,True
285,Placebo,primary,Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial,OG001,Parallel Assignment,Placebo liquid by mouth or Per Tube twice a day,True,False
286,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Factorial Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
287,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Factorial Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
288,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Factorial Assignment,Placebo 1200 mg or 1800 mg,False,False
289,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Factorial Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
290,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Factorial Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
291,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Factorial Assignment,Placebo 1200 mg or 1800 mg,False,False
292,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Factorial Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
293,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Factorial Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
294,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Factorial Assignment,Placebo 1200 mg or 1800 mg,False,False
295,G-ER 1200 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Factorial Assignment,Gabapentin extended-release (G-ER) 1200 mg,False,False
296,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Factorial Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
297,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG002,Factorial Assignment,Placebo 1200 mg or 1800 mg,False,False
298,Gabapentin,primary,Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery,OG000,Parallel Assignment,gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative,False,True
299,Bisoprolol,primary,Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery,OG001,Parallel Assignment,bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative,False,False
300,Control,primary,Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery,OG002,Parallel Assignment,placebo was given to patients of control group 2 hours preoperative,False,False
301,Gabapentin,primary,Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery,OG000,Parallel Assignment,gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative,False,True
302,Bisoprolol,primary,Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery,OG001,Parallel Assignment,bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative,False,False
303,Control,primary,Preoperative Gabapentin Versus Bisoprolol for Intraoperative Hemodynamic and Surgical Field Optimization During Endoscopic Sinus Surgery,OG002,Parallel Assignment,placebo was given to patients of control group 2 hours preoperative,False,False
304,Gabapentin,primary,Gabapentin Treatment of Benzodiazepine Dependence,OG000,Parallel Assignment,"All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.

gabapentin",False,True
305,Placebo,primary,Gabapentin Treatment of Benzodiazepine Dependence,OG001,Parallel Assignment,"Capsules filled with riboflavin.

Placebo",True,False
306,Placebo,primary,Pain Control With Total Knee Replacement: Does Gabapentin Affect Narcotic Usage and Functional Outcome? A Randomized Controlled Trial.,OG000,Parallel Assignment,Placebo- Comparator,True,False
307,Gabapentin,primary,Pain Control With Total Knee Replacement: Does Gabapentin Affect Narcotic Usage and Functional Outcome? A Randomized Controlled Trial.,OG001,Parallel Assignment,Active pain medicine,False,True
308,Placebo,primary,"This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns.",OG000,Parallel Assignment,"Alcohol-dependent subjects spend 3 nights in the UM sleep lab, then are randomized to receive placebo for one week. They then return to the sleep lab for the same procedures.

Placebo dispensed to subjects: Alcohol-dependent subjects have polysomnography in the UM Sleep Lab for three nights, then are randomized to receive placebo for 11 days, (1 pill to represent 600mg at bedtime on nights 1 and 2, 2 pills to represent 1200mg at bedtime on nights 3-10, and 1 pill to represent 600mg at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.",True,False
309,Gabapentin,primary,"This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns.",OG001,Parallel Assignment,"Alcohol-dependent subjects are randomized to receive gabapentin after spending 3 baseline nights in the UM sleep lab. On nights1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8 -10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.",False,True
310,Placebo,primary,"This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns.",OG000,Parallel Assignment,"Alcohol-dependent subjects spend 3 nights in the UM sleep lab, then are randomized to receive placebo for one week. They then return to the sleep lab for the same procedures.

Placebo dispensed to subjects: Alcohol-dependent subjects have polysomnography in the UM Sleep Lab for three nights, then are randomized to receive placebo for 11 days, (1 pill to represent 600mg at bedtime on nights 1 and 2, 2 pills to represent 1200mg at bedtime on nights 3-10, and 1 pill to represent 600mg at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.",True,False
311,Gabapentin,primary,"This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns.",OG001,Parallel Assignment,"Alcohol-dependent subjects are randomized to receive gabapentin after spending 3 baseline nights in the UM sleep lab. On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8 -10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.",False,True
312,1 Placebo,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG000,Parallel Assignment,Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system,True,False
313,2 Gabapentin Low,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG001,Parallel Assignment,Intraspinal Gabapentin Low (1mg/day) delivered continuously for 22 days via an implantable infusion system followed by 7 days of infusion at half dose,False,True
314,3 Gabapentin Medium,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG002,Parallel Assignment,Intraspinal Gabapentin Medium (6mg/day) delivered continuously for 22 days via an implantable infusion system followed by 7 days of infusion at half dose,False,True
315,4 Gabapentin High,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG003,Parallel Assignment,Intraspinal Gabapentin High (30mg/day) delivered continuously for 22 days via an implantable infusion system followed by 7 days of infusion at half dose,False,True
316,1 Placebo,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG000,Parallel Assignment,Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system,True,False
317,2 Gabapentin Low,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG001,Parallel Assignment,Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days of infusion at half dose,False,True
318,3 Gabapentin Medium,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG002,Parallel Assignment,Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days of infusion at half dose,False,True
319,4 Gabapentin High,primary,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",OG003,Parallel Assignment,Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days of infusion at half dose,False,True
320,Gabapentin,primary,Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals,OG000,Parallel Assignment,Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.,False,True
321,Placebo,primary,Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals,OG001,Parallel Assignment,"Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening",True,False
322,GEn 1200 mg,primary,Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.,OG000,Crossover Assignment,GEn 1200 mg daily either in first intervention period or second intervention period,False,False
323,GEn 3600 mg,primary,Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.,OG001,Crossover Assignment,GEn 3600 mg daily either in first intervention period or second intervention period,False,False
324,GEn 1200 mg in First Intervention Period,primary,Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.,OG000,Crossover Assignment,GEn 1200 mg daily in first intervention period only,False,False
325,GEn 3600 mg in First Intervention Period,primary,Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.,OG001,Crossover Assignment,GEn 3600 mg daily in first intervention period only,False,False
326,GEn 1200 mg in Second Intervention Period,primary,Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.,OG002,Crossover Assignment,GEn 1200 mg daily in second intervention period only,False,False
327,GEn 3600 mg in Second Interevention Period,primary,Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.,OG003,Crossover Assignment,GEn 3600 mg daily in second intervention period only,False,False
328,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Parallel Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
329,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Parallel Assignment,Placebo 1800 mg,False,False
330,G-ER 1800 mg,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG000,Parallel Assignment,Gabapentin extended-release (G-ER) 1800 mg,False,False
331,Sugar Pill,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women",OG001,Parallel Assignment,Placebo 1800 mg,False,False
332,Gabapentin/B-complex,primary,"Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain",OG000,Parallel Assignment,"Gabapentin/B-complex (Gavindo®) tablet administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed was 3600 mg/day. The total duration of treatment was 84 days (12 weeks).",False,True
333,Pregabalin,primary,"Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain",OG001,Parallel Assignment,"Pregabalin (Lyrica®) capsule administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed was 600 mg/day. The total duration of treatment was 84 days (12 weeks).",False,False
334,Gralise,primary,"Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome",OG000,Crossover Assignment,Gralise,False,False
335,Placebo,primary,"Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome",OG001,Crossover Assignment,Placebo,True,False
336,Placebo,primary,The Effect of Neurontin on Pain Management in the Acutely Burned Patient,OG000,Parallel Assignment,Patients received a sugar pill similar to gabapentin.,True,False
337,Gabapentin,primary,The Effect of Neurontin on Pain Management in the Acutely Burned Patient,OG001,Parallel Assignment,Patients received gabapentin.,False,True
338,GSK1838262 600 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG000,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,False,False
339,GSK1838262 450 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG001,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,False,False
340,GSK1838262 300 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG002,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,False,False
341,GSK1838262 Placebo Match,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG003,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,True,False
342,GSK1838262 600 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG000,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,False,False
343,GSK1838262 450 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG001,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,False,False
344,GSK1838262 300 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG002,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,False,False
345,GSK1838262 Placebo Match,primary,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)",OG003,Parallel Assignment,Once-daily dose with food in the evening at approximately 5 PM,True,False
346,"Preoperative Gabapentine,",primary,Effect of Preoperative Gabapentine for Carpal Tunnel Syndrome,OG000,Parallel Assignment,"Gabapentine

Gabapentine: Gabapentine 600 mg 01 dose",False,True
347,Sugar Pill,primary,Effect of Preoperative Gabapentine for Carpal Tunnel Syndrome,OG001,Parallel Assignment,"Placebo group

Sugar pill: Sugar pill 01 dose",False,False
348,G-ER,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia",OG000,Parallel Assignment,"Gabapentin Extended Release 1800 mg once daily (qd); 300 mg and 600 mg tablets, oral dosing",False,False
349,Placebo,primary,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia",OG001,Parallel Assignment,"Placebo 1800 mg once daily (qd); 300 mg and 600 mg sugar pills, oral dosing",True,False
350,Donepezil,primary,"Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",OG000,Parallel Assignment,Donepezil 5 mg /day from 2-14 weeks with gabapentin titrated beginning at week 8 and maintained until week 15.,False,False
351,Duloxetine,primary,"Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",OG001,Parallel Assignment,Duloxetine 30 mg twice per day from 2-14 weeks with gabapentin titrated beginning at week 8 and maintained until week 15.,False,False
352,Donepezil + Duloxetine,primary,"Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",OG002,Parallel Assignment,Donepezil 2.5 mg /day and duloxetine 30 mg / day from 2-14 weeks with gabapentin titrated beginning at week 8 and maintained until week 15.,False,False
353,Placebo,primary,"Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",OG003,Parallel Assignment,Placebo from 2-14 weeks with gabapentin titrated beginning at week 8 and maintained until week 15.,True,False
354,Gralise® (Gabapentin),primary,"A Phase 4, Double-Blind, Placebo-Controlled, Crossover Study Comparing Simulated Driving Performance, Daytime Sedation, and Cognition in Healthy Volunteers Taking Therapeutic Doses of Gralise®, Neurontin®, or Lyrica®",OG000,Crossover Assignment,Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.,False,True
355,Neurontin® (Gabapentin),primary,"A Phase 4, Double-Blind, Placebo-Controlled, Crossover Study Comparing Simulated Driving Performance, Daytime Sedation, and Cognition in Healthy Volunteers Taking Therapeutic Doses of Gralise®, Neurontin®, or Lyrica®",OG001,Crossover Assignment,"Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.",False,True
356,Placebo,primary,"A Phase 4, Double-Blind, Placebo-Controlled, Crossover Study Comparing Simulated Driving Performance, Daytime Sedation, and Cognition in Healthy Volunteers Taking Therapeutic Doses of Gralise®, Neurontin®, or Lyrica®",OG002,Crossover Assignment,"Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.",True,False
357,Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG000,Parallel Assignment,Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week; and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
358,MF0434 + Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG001,Parallel Assignment,MF0434 and Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
359,Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG000,Parallel Assignment,Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week; and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
360,MF0434 + Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG001,Parallel Assignment,MF0434 and Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
361,Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG000,Parallel Assignment,Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week; and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
362,MF0434 + Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG001,Parallel Assignment,MF0434 and Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
363,Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG000,Parallel Assignment,Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week; and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
364,MF0434 + Gabapentin,primary,"Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study",OG001,Parallel Assignment,MF0434 and Gabapentin 300 mg capsule was taken orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose for one week and then dose increased up to 3 weeks as per dosage adjustment schedule.,False,True
365,Naltrexone Plus Gabapentin and CBI,primary,Gabapentin as an Adjunct to Naltrexone for Alcoholism,OG000,Factorial Assignment,Naltrexone plus gabapentin and CBI individual counseling for 6 weeks then naltrexone and CBI for 10 additional weeks.,False,True
366,Naltrexone Plus Placebo and CBI,primary,Gabapentin as an Adjunct to Naltrexone for Alcoholism,OG001,Factorial Assignment,Naltrexone plus placebo and CBI individual counseling for 6 weeks then naltrexone and CBI counseling for 10 weeks.,True,False
367,Placebo Plus Placebo Plus CBI,primary,Gabapentin as an Adjunct to Naltrexone for Alcoholism,OG002,Factorial Assignment,Placebo plus placebo for 6 weeks and CBI individual counseling then placebo and CBI counseling for 10 additional weeks.,True,False
368,Gabapentin,primary,"Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy",OG000,Parallel Assignment,"Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.

> dexamethasone: Given orally

> gabapentin: Given orally",False,True
369,Placebo,primary,"Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy",OG001,Parallel Assignment,"Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.

> dexamethasone: Given orally

> placebo: Given orally",True,False
370,Gabapentin Tablets/Syrup,primary,Special Investigation Of Gabapen For Pediatric (Regulatory Post Marketing Commitment Plan),OG000,NA,"For participants aged 13 years or older, 600 mg in 3 divided doses (div.) was administered on day 1 and an effective dose of 1200 mg in 3 div. was administered on day 2. From day 3 on, participants were maintained on 1200 mg to 1800 mg in 3 div. The maintenance dose was adjusted according to the symptoms (up to a maximum daily dose of 2400 mg). For participants aged 3 to 12 years, 10 mg/kg/day was administered orally in 3 div. on day 1 of the treatment, and an effective dose of 20 mg/kg/day was administered in 3 div. on day 2. From day 3 on, participants aged 3 to 4 years were maintained on 40 mg/kg/day in 3 div. and participants aged 5 to 12 years were maintained on 25 to 35 mg/kg/day in 3 div. The maintenance dose was adjusted according to the symptoms (up to a maximum dose of 50 mg/kg/day). At any time point, the dose was not exceeded that for participants aged 13 years or older.",False,True
371,Gabapentin Tablets/Syrup,primary,Special Investigation Of Gabapen For Pediatric (Regulatory Post Marketing Commitment Plan),OG000,NA,"For participants aged 13 years or older, 600 mg in 3 divided doses (div.) was administered on day 1 and an effective dose of 1200 mg in 3 div. was administered on day 2. From day 3 on, participants were maintained on 1200 mg to 1800 mg in 3 div. The maintenance dose was adjusted according to the symptoms (up to a maximum daily dose of 2400 mg). For participants aged 3 to 12 years, 10 mg/kg/day was administered orally in 3 div. on day 1 of the treatment, and an effective dose of 20 mg/kg/day was administered in 3 div. on day 2. From day 3 on, participants aged 3 to 4 years were maintained on 40 mg/kg/day in 3 div. and participants aged 5 to 12 years were maintained on 25 to 35 mg/kg/day in 3 div. The maintenance dose was adjusted according to the symptoms (up to a maximum dose of 50 mg/kg/day). At any time point, the dose was not exceeded that for participants aged 13 years or older.",False,True
372,Pregabalin,primary,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",OG000,Parallel Assignment,"Pregabalin was initiated at 150 mg/day [50 mg capsules orally three times a day (TID)] for 1 Week followed by pregabalin 300 mg/day (100 mg TID) orally TID up to Week 5 in the Titration Phase (TP). Participants who had adequate seizure control (adequate: >=50% reduction in seizures) with acceptable tolerability with pregabalin 300 mg/day in TP, continued same dose until the end of TP (Week 9) and then entered the maintenance phase (MP) on this dose. If seizure control was inadequate, the pregabalin dose was escalated to 450 mg/day orally (150 mg TID) from Weeks 5 through 9. If the participants had adequate seizure control with acceptable tolerability on this dose, then they entered the MP on this dose. If there was inadequate seizure control at the end of Week 9, the dose was escalated a final time to 600 mg/day (200 mg TID) at which time they entered the MP.",False,False
373,Gabapentin,primary,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.",OG001,Parallel Assignment,"Gabapentin was initiated at 300 mg/day [100 mg capsules orally three times a day (TID)] followed by gabapentin 600 mg/day (200 mg TID) on Day 3. At the end of Week 1 (Day 7), the dose was increased to 1200 mg/day (400 mg TID) and remained on this dose for the next 4 weeks). Participants who had adequate seizure control (>=50% reduction in seizure frequency) with acceptable tolerability during this initial 5-week period, remained on this dose until the end of theTP (Week 9), then entered the MP on this dose. If seizure control was inadequate, the gabapentin dose was escalated to 1500 mg/day (500 mg TID) during Weeks 5 through 9. If they had adequate seizure control with acceptable tolerability on this dose, they entered the MP on this dose. If there was inadequate seizure control at the end of Week 9, the dose was escalated a final time to 1800 mg/day (600 mg TID), at which time they entered the MP.",False,True
374,Arm I Standard of Care,primary,A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation,OG000,Parallel Assignment,"Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.

Educational Intervention: Undergo oral care and pain management education session

Pain Therapy: Receive usual oral health care

Quality-of-Life Assessment: Ancillary studies

Questionnaire Administration: Ancillary studies

Oxycodone/Acetaminophen: Analgesia

Hydrocodone/Acetaminophen: Analgesia

Fentanyl: Transdermal Analgesia

Ibuprofen: NSAID Analgesia

Magic Mouthwash: Oral Solution to treat mucositis",False,False
375,Arm II Standard of Care Plus Gabapentin,primary,A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation,OG001,Parallel Assignment,"Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.

Educational Intervention: Undergo oral care and pain management education session

Gabapentin: Given PO

Pain Therapy: Receive usual oral health care

Quality-of-Life Assessment: Ancillary studies

Questionnaire Administration: Ancillary studies

Oxycodone/Acetaminophen: Analgesia

Hydrocodone/Acetaminophen: Analgesia

Fentanyl: Transdermal Analgesia

Ibuprofen: NSAID Analgesia

Magic Mouthwash: Oral Solution to treat mucositis",False,True
376,Gabapentin,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG000,Crossover Assignment,Gabapentin single oral 1200 mg dose,False,True
377,Morphine,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG001,Crossover Assignment,Morphine single IV 10 mg dose,False,False
378,Diphenhydramine,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG002,Crossover Assignment,Diphenhydramine single oral 50 mg dose,False,False
379,Placebo,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG003,Crossover Assignment,Oral and IV doses to match active treatments,True,False
380,Gabpentin,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG000,Crossover Assignment,Gabapentin 1200 mg,False,False
381,Morphine,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG001,Crossover Assignment,Morphine 10 mg,False,False
382,Diphenhydramine,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG002,Crossover Assignment,Diphenhydramine single oral 50 mg dose,False,False
383,Placebo,primary,"A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers",OG003,Crossover Assignment,Oral and IV doses to match active treatments,True,False
384,Pregabalin,primary,"An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain",OG000,Parallel Assignment,"Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.",False,False
385,Duloxetine,primary,"An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain",OG001,Parallel Assignment,"Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.",False,False
386,Gabapentin,primary,Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?,OG000,Parallel Assignment,Gabapentin titrated to 2400 mg daily PO for 5 weeks,False,True
387,Placebo,primary,Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?,OG001,Parallel Assignment,Matched placebo group underwent identical 'titration' as intervention group.,True,False
388,Placebo,primary,Sertraline Augmented With GABA Agents for Cocaine Dependence,OG000,Parallel Assignment,NA,True,False
389,Sertraline,primary,Sertraline Augmented With GABA Agents for Cocaine Dependence,OG001,Parallel Assignment,NA,False,False
390,Sertraline Plus Gabapentin,primary,Sertraline Augmented With GABA Agents for Cocaine Dependence,OG002,Parallel Assignment,NA,False,True
391,Low CIWA Flumazenil/Gabapentin,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG000,Parallel Assignment,2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.,False,True
392,Low CIWAar Placebo,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG001,Parallel Assignment,"20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.",True,False
393,High CIWAar Placebo,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG002,Parallel Assignment,"20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.",True,False
394,High CIWAar Flumazenil/Gabapentin,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG003,Parallel Assignment,2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.,False,True
395,Low CIWA Flumazenil/Gabapentin,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG000,Parallel Assignment,2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.,False,True
396,Low CIWAar Placebo,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG001,Parallel Assignment,"20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.",True,False
397,High CIWAar Placebo,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG002,Parallel Assignment,"20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.",True,False
398,High CIWAar Flumazenil/Gabapentin,primary,A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention,OG003,Parallel Assignment,2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.,False,True
399,Placebo,primary,Efficacy of Antidepressants in Chronic Back Pain,OG000,Parallel Assignment,"Inert placebo capsules, 3 capsules three times a day for 12 weeks",True,False
400,Gabapentin,primary,Efficacy of Antidepressants in Chronic Back Pain,OG001,Parallel Assignment,gabapentin capsule 1200mg three times a day for 12 weeks,False,True
401,Gabapentin,primary,Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol,OG000,Parallel Assignment,"Active treatment arm.

gabapentin: Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.",False,True
402,Placebo,primary,Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol,OG001,Parallel Assignment,"Placebo arm.

placebo: Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.",True,False
403,Control,primary,Stanford Accelerated Recovery Trial (START),OG000,Parallel Assignment,"Active placebo (lorazepam 0.5 mg) given pre-operatively, followed by inactive placebo for 10 doses post-operatively.",False,False
404,Gabapentin,primary,Stanford Accelerated Recovery Trial (START),OG001,Parallel Assignment,"1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.",False,True
405,Naïve; 1200 mg GEn,primary,"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.",OG000,Single Group Assignment,"Naïve participants received placebo (therefore naïve to gabapentin enacarbil [GEn]) in a parent study, followed by GEn 1200 mg once a day (with the flexibility to go up to 1800 mg or down to 600 mg based on tolerability and efficacy) in this study.",False,False
406,Non-naïve; 1200 mg GEn,primary,"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.",OG001,Single Group Assignment,"Non-naïve participants received GEn in a parent study, followed by GEn 1200 mg once a day (with the flexibility to go up to 1800 mg or down to 600 mg based on tolerability and efficacy) in this study.",False,False
407,All Participants; 1200 mg GEn,primary,"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.",OG002,Single Group Assignment,"All participants received GEn or placebo in a parent study, followed by GEn 1200 mg once a day (with the flexibility to go up to 1800 mg or down to 600 mg based on tolerability and efficacy) in this study.",False,False
408,Naïve; 1200 mg GEn,primary,"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.",OG000,Single Group Assignment,"Naïve participants received placebo (therefore naïve to gabapentin enacarbil [GEn]) in a parent study, followed by GEn 1200 mg once a day (with the flexibility to go up to 1800 mg or down to 600 mg based on tolerability and efficacy) in this study.",False,False
409,Non-naïve; 1200 mg GEn,primary,"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.",OG001,Single Group Assignment,"Non-naïve participants received GEn in a parent study, followed by GEn 1200 mg once a day (with the flexibility to go up to 1800 mg or down to 600 mg based on tolerability and efficacy) in this study.",False,False
410,All Participants; 1200 mg GEn,primary,"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.",OG002,Single Group Assignment,"All participants received GEn or placebo in a parent study, followed by GEn 1200 mg once a day (with the flexibility to go up to 1800 mg or down to 600 mg based on tolerability and efficacy) in this study.",False,False
411,DB Placebo,primary,A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.,OG000,Parallel Assignment,"Days 169 to 182: one 600 mg ER tablet of GEn and one matching placebo tablet for a 2-week blinded taper period. Days 183 to 252: two blinded placebo tablets. Days 253 to 260, participants tapered to one placebo tablet",True,False
412,DB GEn 1200 mg,primary,A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.,OG001,Parallel Assignment,"Days 169 to 252: two 600 mg ER tablets (1200 mg GEn). Days 253 to 260, participants tapered to one 600 mg ER tablet",False,False
413,All Antiepileptic Drugs,primary,"Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice",OG000,Single Group Assignment,"Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice",False,False
414,Modafinil,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG000,Parallel Assignment,"Modafinil 200 mg will be administered orally one time

Modafinil",False,False
415,Placebo,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG001,Parallel Assignment,"A placebo will be administered orally one time

Placebo",True,False
416,Gabapentin,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG002,Parallel Assignment,"Gabapentin 900 mg will be administered orally one time

Gabapentin",False,True
417,Modafinil,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG000,Parallel Assignment,"Modafinil 200 mg will be administered orally one time

Modafinil",False,False
418,Placebo,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG001,Parallel Assignment,"A placebo will be administered orally one time

Placebo",True,False
419,Gabapentin,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG002,Parallel Assignment,"Gabapentin 900 mg will be administered orally one time

Gabapentin",False,True
420,Modafinil,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG000,Parallel Assignment,"Modafinil 200 mg will be administered orally one time

Modafinil",False,False
421,Placebo,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG001,Parallel Assignment,"A placebo will be administered orally one time

Placebo",True,False
422,Gabapentin,primary,A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip,OG002,Parallel Assignment,"Gabapentin 900 mg will be administered orally one time

Gabapentin",False,True
423,Open Label - Cohort >70 Yrs Old,primary,"A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice",OG000,NA,"Cohort by age-

- Patients >70 Yrs old",False,False
424,Open Label - Cohort <=70 Yrs Old,primary,"A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice",OG001,NA,"Cohort by age-

- Patients <=70 Yrs old",False,False
425,Placebo,primary,Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN),OG000,Parallel Assignment,"Three 600 milligram (mg) gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, placebo tablets taken orally twice daily (morning and evening)",True,False
426,GEn 1200 mg/Day,primary,Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN),OG001,Parallel Assignment,One 600 mg GEn tablet and two GEn placebo tablets taken orally twice daily (morning and evening),False,False
427,GEn 2400 mg/Day,primary,Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN),OG002,Parallel Assignment,Two 600 mg GEn tablets and one GEN placebo tablet taken orally twice daily (morning and evening),False,False
428,GEn 3600 mg/Day,primary,Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN),OG003,Parallel Assignment,Three 600 mg GEn tablets taken orally twice daily (morning and evening),False,False
429,Furosemide + Enhanced Recovery After Surgery (ERAS),primary,"A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery",OG000,Parallel Assignment,"Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.",False,False
430,Enhanced Recovery After Surgery (ERAS),primary,"A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery",OG001,Parallel Assignment,"ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.",False,False
431,Placebo,primary,"Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)",OG000,Parallel Assignment,"Three 600 milligram (mg) gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, placebo tablets taken orally twice daily (morning and evening); one 100 mg pregabalin (PGB) placebo capsule taken orally three times daily (morning, midday, and evening).",True,False
432,GEn 1200 mg/Day,primary,"Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)",OG001,Parallel Assignment,"One 600 mg extended release (ER) GEn tablet and two 600 mg GEn placebo tablets taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).",False,False
433,GEn 2400 mg/Day,primary,"Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)",OG002,Parallel Assignment,"Two 600 mg ER GEn tablets and one 600 mg GEn placebo tablet taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).",False,False
434,GEn 3600 mg/Day,primary,"Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)",OG003,Parallel Assignment,"Three 600 mg ER GEn tablets taken orally twice daily (morning and evening); one 100 mg PGB placebo capsule taken orally three times daily (morning, midday, and evening).",False,False
435,PGB 300 mg/Day,primary,"Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)",OG004,Parallel Assignment,"Three 600 mg GEn placebo tablets taken orally twice daily (morning and evening); one 100 mg PGB capsule taken orally three times daily (morning, midday, and evening).",False,False
436,GEn Placebo,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG000,Parallel Assignment,"Oral placebo tablet taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 6: two placebo tablets. Days 7 to 9: three placebo tablets. Days 10 to 84: four placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",True,False
437,GEn 600 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG001,Parallel Assignment,"Gabapentin enacarbil (GEn) (XP13512/GSK1838262) 600 milligrams (mg) taken orally once a day for 12 weeks. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 6: one ER tablet (600 mg GEn) and one placebo tablet. Days 8 to 10: one ER tablet (600 mg GEn) and two placebo tablets. Days 10 to 84: one ER tablet (600 mg GEn) and three placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",False,False
438,GEn 1200 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG002,Parallel Assignment,"Oral GEn 1200 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: two ER tablets (1200 mg GEn) and one placebo tablet. Days 10 to 84: two ER tablets (1200 mg GEn) and two placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: one ER tablet (600 mg GEn) and two placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",False,False
439,GEn 1800 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG003,Parallel Assignment,"Oral GEn 1800 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: three ER tablets (1800 mg GEn). Days 10 to 84: three ER tablets (1800 mg GEn) and one placebo tablet. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: two ER tablets (1200 mg GEn) and one placebo tablet. Days 87 to 88: one ER tablet (600 mg) and one placebo tablet. Days 89 to 91: one placebo tablet.",False,False
440,GEn 2400 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG004,Parallel Assignment,"Oral GEn 1200 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: three ER tablets (1800 mg GEn). Days 10 to 84: four ER tablets (2400 mg GEn). On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three ER tablets (1800 mg GEn). Days 87 to 88: two ER tablets (1200 mg). Days 89 to 91: one ER (600 mg) tablet.",False,False
441,GEn Placebo,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG000,Parallel Assignment,"Oral placebo tablet taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 6: two placebo tablets. Days 7 to 9: three placebo tablets. Days 10 to 84: four placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",True,False
442,GEn 600 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG001,Parallel Assignment,"Gabapentin enacarbil (GEn) (XP13512/GSK1838262) 600 milligrams (mg) taken orally once a day for 12 weeks. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 6: one ER tablet (600 mg GEn) and one placebo tablet. Days 8 to 10: one ER tablet (600 mg GEn) and two placebo tablets. Days 10 to 84: one ER tablet (600 mg GEn) and three placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",False,False
443,GEn 1200 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG002,Parallel Assignment,"Oral GEn 1200 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: two ER tablets (1200 mg GEn) and one placebo tablet. Days 10 to 84: two ER tablets (1200 mg GEn) and two placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: one ER tablet (600 mg GEn) and two placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",False,False
444,GEn 1800 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG003,Parallel Assignment,"Oral GEn 1800 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: three ER tablets (1800 mg GEn). Days 10 to 84: three ER tablets (1800 mg GEn) and one placebo tablet. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: two ER tablets (1200 mg GEn) and one placebo tablet. Days 87 to 88: one ER tablet (600 mg) and one placebo tablet. Days 89 to 91: one placebo tablet.",False,False
445,GEn 2400 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG004,Parallel Assignment,"Oral GEn 1200 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: three ER tablets (1800 mg GEn). Days 10 to 84: four ER tablets (2400 mg GEn). On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three ER tablets (1800 mg GEn). Days 87 to 88: two ER tablets (1200 mg). Days 89 to 91: one ER (600 mg) tablet.",False,False
446,GEn Placebo,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG000,Parallel Assignment,"Oral placebo tablet taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 6: two placebo tablets. Days 7 to 9: three placebo tablets. Days 10 to 84: four placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",True,False
447,GEn 600 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG001,Parallel Assignment,"Gabapentin enacarbil (GEn) (XP13512/GSK1838262) 600 milligrams (mg) taken orally once a day for 12 weeks. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 6: one ER tablet (600 mg GEn) and one placebo tablet. Days 8 to 10: one ER tablet (600 mg GEn) and two placebo tablets. Days 10 to 84: one ER tablet (600 mg GEn) and three placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",False,False
448,GEn 1200 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG002,Parallel Assignment,"Oral GEn 1200 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: two ER tablets (1200 mg GEn) and one placebo tablet. Days 10 to 84: two ER tablets (1200 mg GEn) and two placebo tablets. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: one ER tablet (600 mg GEn) and two placebo tablets. Days 87 to 88: two placebo tablets. Days 89 to 91: one placebo tablet.",False,False
449,GEn 1800 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG003,Parallel Assignment,"Oral GEn 1800 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: three ER tablets (1800 mg GEn). Days 10 to 84: three ER tablets (1800 mg GEn) and one placebo tablet. On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: two ER tablets (1200 mg GEn) and one placebo tablet. Days 87 to 88: one ER tablet (600 mg) and one placebo tablet. Days 89 to 91: one placebo tablet.",False,False
450,GEn 2400 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome",OG004,Parallel Assignment,"Oral GEn 1200 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 6: two ER tablets (1200 mg GEn). Days 8 to 10: three ER tablets (1800 mg GEn). Days 10 to 84: four ER tablets (2400 mg GEn). On Day 85, participants entered a 7-day Taper Period. Days 85 to 86: three ER tablets (1800 mg GEn). Days 87 to 88: two ER tablets (1200 mg). Days 89 to 91: one ER (600 mg) tablet.",False,False
451,"Multimodal:Acetaminophen, Gabapentin, Ketamine, Bupivacaine",primary,ACL Repair and Multimodal Analgesia,OG000,Single Group Assignment,"aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane

multimodal:acetaminophen, gabapentin, ketamine, bupivacaine: acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane",False,True
452,Placebo Pills and Injectables,primary,ACL Repair and Multimodal Analgesia,OG001,Single Group Assignment,"standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane

placebo pills and injectables: receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds",True,False
453,Placebo,primary,"Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance",OG000,Crossover Assignment,Placebo once daily either in first intervention period or second intervention period,True,False
454,GEn 1200 mg,primary,"Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance",OG001,Crossover Assignment,GEn 1200 mg once daily either in first intervention period or second intervention period,False,False
455,Placebo,primary,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.",OG000,Parallel Assignment,Oral placebo tablet taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 84: two placebo tablets. On Days 85 participants entered a 7-day Taper Period. Days 85 to 91: one placebo tablet.,True,False
456,GEn (XP13512/GSK1838262) 1200 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.",OG001,Parallel Assignment,"Oral GEn (gabapentin enacarbil) 1200 milligrams (mg) taken once daily. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 84: two ER tablets (1200 mg GEn). On Day 85, participants entered a 7-day Taper Period. Days 85 to 91: one ER tablet (600 mg GEn).",False,False
457,Placebo,primary,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.",OG000,Parallel Assignment,Oral placebo tablet taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 84: two placebo tablets. On Days 85 participants entered a 7-day Taper Period. Days 85 to 91: one placebo tablet.,True,False
458,GEn (XP13512/GSK1838262) 1200 mg,primary,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.",OG001,Parallel Assignment,"Oral GEn (gabapentin enacarbil) 1200 milligrams (mg) taken once daily. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 84: two ER tablets (1200 mg GEn). On Day 85, participants entered a 7-day Taper Period. Days 85 to 91: one ER tablet (600 mg GEn).",False,False
459,GEn Placebo and DPH Placebo,primary,"A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome",OG000,Parallel Assignment,"Oral gabapentin enacarbil (GEn) placebo taken once daily. Days 1 to 3: one placebo tablet. Days 4 to 7: two placebo tablets. Days 8 to 16: three placebo tablets. On Day 16, participants also took two capsules of diphenhydramine (DPH) placebo. On Day 17, participants entered a 7-day Taper Period. Days 17 to 20: two placebo tablets. Days 21 to 23: one placebo tablet.",True,False
460,GEn 1200 mg and DPH Placebo,primary,"A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome",OG001,Parallel Assignment,"Oral GEn (XP13512/GSK1838262) 1200 milligrams (mg) taken once daily. Days 1 to 3: one extended release (ER) tablet (600 mg GEn). Days 4 to 7: two ER tablets (600 mg GEn each). Days 8 to 16: two ER tablets (600 mg GEn each) and one placebo tablet. On Day 16, participants also took two capsules of DPH placebo. On Day 17, participants entered a 7-day Taper Period. Days 17 to 20: one ER tablet (600 mg GEn) and one placebo tablet. Days 21 to 23: one ER tablet (600 mg GEn).",True,False
461,GEn 1800 mg and DPH Placebo,primary,"A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome",OG002,Parallel Assignment,"Oral GEn (XP13512/GSK1838262) 1800 mg taken once daily. Days 1 to 3: one ER tablet (600 mg GEn). Days 4 to 7: two ER tablets (600 mg GEn each). Days 8 to 16: three ER tablets (600 mg GEn each). On Day 16, participants also took two capsules of DPH placebo. On Day 17, participants entered a 7-day Taper Period. Days 17 to 20: two ER tablets (600 mg GEn each) and one placebo tablet. Days 21 to 23: one ER tablet (600 mg GEn).",True,False
462,GEn Placebo and DPH 50 mg on Day 16,primary,"A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome",OG003,Parallel Assignment,"Oral GEn placebo taken once daily and oral DPH 50 mg taken once on Day 16. Days 1 to 3: one placebo tablet. Days 4 to 7: two placebo tablets. Days 8 to 16: three placebo tablets. On Day 16, participants also took two capsules of DPH (25 mg DPH each). On Day 17, participants entered a 7-day Taper Period. Days 17 to 20: two placebo tablets. Days 21 to 23: one placebo tablet.",True,False
463,Donepezil,primary,Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain,OG000,Parallel Assignment,"donepezil 5 mg every day

Donepezil: donepezil 5 mg once daily for 6 weeks",False,False
464,Placebo,primary,Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain,OG001,Parallel Assignment,"Placebo (sugar pill) every day

Placebo: placebo or sugar pill will be taken once daily for 6 weeks",True,False
465,Observational,primary,Opioid-Free Shoulder Arthroplasty,OG000,Parallel Assignment,"The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.",False,False
466,Non-Opioid Intervention,primary,Opioid-Free Shoulder Arthroplasty,OG001,Parallel Assignment,"Oral dose of gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but included one dose of IV acetaminophen during procedure. Anesthetic modalities include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). PRN medications will include acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.",False,False
467,No Choice,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG000,Parallel Assignment,"No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h

No choice given: Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Morphine (med): Intrathecal morphine dose 150mcg",False,False
468,Choice: Low Protocol,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG001,Parallel Assignment,"Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h

Choice given: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Morphine (low): Intrathecal morphine dose 50mcg",False,False
469,Choice: Medium Protocol,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG002,Parallel Assignment,"Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h

Choice given: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Morphine (med): Intrathecal morphine dose 150mcg",False,False
470,Choice: High Protocol,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG003,Parallel Assignment,"Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose

Choice given: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Gabapentin: Gabapentin 600mg po one time within 1 hour of delivery

Morphine (high): Intrathecal morphine 300mcg",False,False
471,No Choice,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG000,Parallel Assignment,"No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h

No choice given: Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Morphine (med): Intrathecal morphine dose 150mcg",False,False
472,Choice: Low Protocol,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG001,Parallel Assignment,"Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h

Choice given: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Morphine (low): Intrathecal morphine dose 50mcg",False,False
473,Choice: Medium Protocol,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG002,Parallel Assignment,"Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h

Choice given: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Morphine (med): Intrathecal morphine dose 150mcg",False,False
474,Choice: High Protocol,primary,Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management,OG003,Parallel Assignment,"Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose

Choice given: Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.

Ibuprofen: Ibuprofen 600mg po q6h

Acetaminophen: Acetaminophen 650mg po q6h

Gabapentin: Gabapentin 600mg po one time within 1 hour of delivery

Morphine (high): Intrathecal morphine 300mcg",False,False
475,Study Drug CC 10004,primary,A Clinical Trial Of CC-10004 For The Treatment Of Vulvodynia,OG000,Single Group Assignment,Study drug CC-10004 20mg taken orally twice a day for 12 weeks.,False,False
476,Control Group (C),primary,Pregabalin for the Treatment of Pain After Posterior Spinal Fusions.,OG000,Parallel Assignment,Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.,False,False
477,Pregabalin Group (P),primary,Pregabalin for the Treatment of Pain After Posterior Spinal Fusions.,OG001,Parallel Assignment,"Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.",False,False
478,Lamotrigine vs Placebo,primary,Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI,OG000,Crossover Assignment,"The drug lamotrigine will be given for 9 weeks prior to imaging session. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. Placebo will be administered in another imaging session. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.",True,False
479,"Medicaid, Uncontrolled, Subgroup",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG000,NA,"Database records for participants with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the next 365 days. This subgroup was matched with participant records in the Medicaid, well-controlled cohort",False,False
480,"Medicaid, Well Controlled",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG001,NA,Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits,False,False
481,"Medicaid, Uncontrolled",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG002,NA,Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy,False,False
482,"Medicaid, Intermediate",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG003,NA,Database records for participants who are not classified as uncontrolled or well controlled,False,False
483,"Private, Uncontrolled, Subgroup",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG004,NA,"Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This subgroup was matched with participant records in the private, well-controlled cohort.",False,False
484,"Private, Well Controlled",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG005,NA,Database records for participants with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visit,False,False
485,"Private, Uncontrolled",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG006,NA,Database records for participants with 2 or more consecutive changes in AED therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visit within the next 365 days. This arm represents all participant records that met the criteria for uncontrolled epilepsy.,False,False
486,"Private, Intermediate",primary,Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database,OG007,NA,Database records for participants who are not classified as uncontrolled or well controlled,False,False
487,Medical Care,primary,A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis,OG000,Parallel Assignment,"Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient. These include any of the following:

NSAIDs, Adjunctive analgesics, antidepressants,

Lumbar epidural injection: prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications. Shared decision making with patient.",False,False
488,Group Exercise,primary,A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis,OG001,Parallel Assignment,"Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.

Group Exercise: community setting: The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.",False,False
489,Manual Therapy and Exercise,primary,A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis,OG002,Parallel Assignment,"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used by physical therapists and chiropractors. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments provided by licensed physical therapists and chiropractors include:

Manual Therapy: Joint mobilizations of the lumbar spine, sacroiliac, and/or hip joints, as well as muscle stretching and neural mobilizations.

Rehabilitative exercises: exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor.",False,False
490,Spine Surgery Analgesic Pathway,primary,Evaluation of Spine Surgery Analgesic Pathway: A Randomized Controlled Trial,OG000,Parallel Assignment,"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).

During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).

After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed.

Spine surgery analgesic pathway: Enhanced pain management care",False,False
491,Usual Care,primary,Evaluation of Spine Surgery Analgesic Pathway: A Randomized Controlled Trial,OG001,Parallel Assignment,"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).

Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).

After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed.

Usual Care: Standard of pain management care",False,False
492,Medications,primary,Novel Topical Therapies for the Treatment of Genital Pain,OG000,Crossover Assignment,"Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.

Amitriptyline: Topical application of the drug at a 2% concentration in combination with 2% Baclofen

Baclofen: Used topically at 2% concentration in combination with 2% amitriptyline

Ketoprofen: To be applied topically at a 10% concentration

Ketamine: To be applied topically at a 10% concentration

Loperamide: To be applied topically at a 5% concentration

Gabapentin: To be applied topically at a 6% concentration",False,False
493,Placebo,primary,Novel Topical Therapies for the Treatment of Genital Pain,OG001,Crossover Assignment,"The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.

placebo: Compounding base to be used alone as a placebo",True,False
494,Lumbar Plexus,primary,Improvement in Total Hip Arthroplasty Patient Outcomes With Regional Anesthesia and Multimodal Analgesia: A Retrospective Analysis,OG000,NA,"Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.",False,False
495,Lumbar Epidural,primary,Improvement in Total Hip Arthroplasty Patient Outcomes With Regional Anesthesia and Multimodal Analgesia: A Retrospective Analysis,OG001,NA,"Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.",False,False
496,nonp450,primary,A Pharmacokinetic Study of the Interaction Between Celecoxib and Anticonvulsant Drugs in Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Radiation Therapy,OG000,Parallel Assignment,"not on p450 inhibitor

celecoxib :

radiation therapy :",False,False
497,p450,primary,A Pharmacokinetic Study of the Interaction Between Celecoxib and Anticonvulsant Drugs in Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Radiation Therapy,OG001,Parallel Assignment,"on p450 inhibitor

celecoxib :

radiation therapy :",False,False
498,Arm 1 +EIASD (Enzyme-inducing Antizeizure Drug),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG000,Parallel Assignment,"subjects on the +EIASD (Level 1) treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.

Subjects will take terameprocol for 5 consecutive days each month by IV. Various Dose levels 1= 750mg/dayx5; 2=1100mg/dayx5; 3=1700mg/dayx5; 4=2200mg/dayx5

NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion",False,False
499,ARM 2 -EIASD (Enzyme-inducing Antizeizure Drug),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG001,Parallel Assignment,"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.

Subjects will take terameprocol for 5 consecutive days each month by IV. Various Dose levels 1= 750mg/dayx5; 2=1100mg/dayx5; 3=1700mg/dayx5; 4=2200mg/dayx5

NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion",False,False
500,ARM 3 (No Stratification),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG002,Parallel Assignment,"Subjects in this group were not stratified based on anti-sezuire medication..

Subjects will take terameprocol for 5 consecutive days each month by IV. This was for dose 2200mg/day.

New formulation TC6.",False,False
501,+ EIASD Level 1 (750 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG000,Parallel Assignment,"subjects on the +EIASD (Level 1) treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.

Subjects will take terameprocol for 5 consecutive days each month by IV. Dose level 1= 750mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation",False,False
502,+EIASD Level 2 (1100 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG001,Parallel Assignment,"subjects on the +EIASD (Level 2) treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.

Subjects will take terameprocol for 5 consecutive days each month by IV. Dose level 2= 1100mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation",False,False
503,+EIASD Level 3 (1700 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG002,Parallel Assignment,"subjects on the +EIASD (Level 3) treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.

Subjects will take terameprocol for 5 consecutive days each month by IV. Dose level 3= 1700mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation; Includes patientss at the new formulation TC6 (-PEG)",False,False
504,+EIASD Level 4 (2200 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG003,Parallel Assignment,"subjects on the +EIASD (Level 4) treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.

Subjects will take terameprocol for 5 consecutive days each month by IV. Dose level 4= 2220mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation",False,False
505,-EIASD Level 1 (750 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG004,Parallel Assignment,"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.

Subjects will take terameprocol for 5 consecutive days each month by IV. Level 1 = 750mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation",False,False
506,-EIASD Level 2 (1100 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG005,Parallel Assignment,"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.

Subjects will take terameprocol for 5 consecutive days each month by IV. Level 2 = 1100mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation",False,False
507,-EIASD Level 3 (1700 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG006,Parallel Assignment,"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.

Subjects will take terameprocol for 5 consecutive days each month by IV. Level 3 = 1700mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation and new TC6 -PEG Formulation - Pts treated from both formulations",False,False
508,-EIASD Level 4 (2200 mg/dayx5D),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG007,Parallel Assignment,"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.

Subjects will take terameprocol for 5 consecutive days each month by IV. Level 4 = 2200mg/day. NO intrasubject dose escalation.

PK data will be collected on day one of cycle one infusion

+PEG Formulation",False,False
509,Non Stratified (Both +EIASD and -EIASD),primary,Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma,OG008,Parallel Assignment,"Subjects in this group were not stratified based on anti-sezuire medication..

Subjects will take terameprocol for 5 consecutive days each month by IV. This was for dose 2200mg/day.

New formulation TC6 - NONPEG or -PEG. (polyethylene glycol )",False,False
510,Usual Care,primary,Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans,OG000,Parallel Assignment,Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.,False,False
511,Stepped Care,primary,Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans,OG001,Parallel Assignment,"Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.

Pain self-management program : The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.

Cognitive behavioral therapy : Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.

Co-Analgesic Therapy",False,False
512,Usual Care,primary,Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans,OG000,Parallel Assignment,Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.,False,False
513,Stepped Care,primary,Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans,OG001,Parallel Assignment,"Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.

Pain self-management program : The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.

Cognitive behavioral therapy : Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.

Co-Analgesic Therapy",False,False
514,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
515,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
516,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
517,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
518,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
519,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
520,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
521,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
522,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
523,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
524,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
525,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
526,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
527,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
528,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
529,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
530,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
531,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
532,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
533,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
534,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
535,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
536,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
537,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
538,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
539,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
540,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
541,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
542,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
543,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
544,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
545,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
546,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
547,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
548,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
549,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
550,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
551,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
552,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
553,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
554,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
555,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
556,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
557,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
558,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
559,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
560,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
561,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
562,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
563,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
564,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
565,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
566,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
567,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
568,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
569,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
570,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
571,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
572,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
573,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
574,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
575,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
576,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
577,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
578,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
579,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
580,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
581,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
582,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
583,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
584,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
585,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
586,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
587,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
588,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
589,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
590,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
591,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
592,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
593,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
594,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
595,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
596,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
597,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
598,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
599,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
600,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
601,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
602,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
603,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
604,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
605,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
606,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
607,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
608,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
609,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
610,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
611,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
612,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
613,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
614,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
615,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
616,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
617,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
618,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
619,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
620,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
621,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
622,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
623,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
624,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
625,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
626,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
627,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
628,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
629,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
630,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
631,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
632,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
633,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
634,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
635,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
636,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
637,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
638,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
639,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
640,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
641,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
642,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
643,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
644,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
645,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
646,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
647,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
648,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
649,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
650,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
651,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
652,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
653,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
654,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
655,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
656,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
657,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
658,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
659,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
660,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
661,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
662,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
663,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
664,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
665,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
666,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
667,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
668,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
669,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
670,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
671,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
672,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
673,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
674,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
675,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
676,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
677,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
678,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
679,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
680,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
681,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
682,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
683,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
684,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
685,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
686,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
687,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
688,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
689,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
690,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
691,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
692,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
693,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
694,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
695,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
696,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
697,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
698,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
699,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
700,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
701,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
702,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
703,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
704,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
705,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
706,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
707,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
708,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
709,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
710,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
711,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
712,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
713,Methotrexate (MTX) + Tofacitinib: MTX Persistent,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG000,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with no gap of >60 days in MTX therapy (persistent) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
714,Methotrexate (MTX) + Tofacitinib: MTX Discontinued,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG001,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days in MTX therapy (discontinued) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
715,Methotrexate (MTX) + Tofacitinib: MTX Interrupted,primary,Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database,OG002,NA,"RA diagnosed participants who were privately insured or under Medicare Supplemental insurance (from their employer), initiated tofacitinib in combination with MTX, orally, between 01 January 2014 to 31 January 2017 (identification period) with a gap of >60 days with 1 or more subsequent prescription re-fills in MTX therapy (interrupted) within 12 months post-index date, were included in the study and their information as per Truven Health MarketScan Research Database (from January 1, 2012 to January 2018) was assessed in this study. Index date defined as the date of first claim for tofacitinib by participants to their insurance provider during identification period.",False,False
716,Pregabalin,primary,NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions In Denmark,OG000,NA,Participants who were diagnosed with peripheral neuropathic pain and met the usual prescribing criteria for pregabalin (Lyrica) as per the local product information were observed for a period of 3 months.,False,False
717,Pregabalin,primary,NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions In Denmark,OG000,NA,Participants who were diagnosed with peripheral neuropathic pain and met the usual prescribing criteria for pregabalin (Lyrica) as per the local product information were observed for a period of 3 months.,False,False
718,Pregabalin,primary,NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions In Denmark,OG000,NA,Participants who were diagnosed with peripheral neuropathic pain and met the usual prescribing criteria for pregabalin (Lyrica) as per the local product information were observed for a period of 3 months.,False,False
719,A: Localized Resectable Disease,primary,"A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma",OG000,Parallel Assignment,"Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.",False,False
720,C: Metastatic Tumors,primary,"A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma",OG001,Parallel Assignment,Stratum C participants had metastatic tumors.,False,False
721,A: Localized Resectable Disease,primary,"A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma",OG000,Parallel Assignment,"OS2008 Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.",False,False
